Japan Recommends Eisai Breast Cancer Agent Eribulin For Approval
This article was originally published in PharmAsia News
Executive Summary
The Second Committee on New Drugs at the Ministry of Health, Labor and Welfare has recommended Eisai's Halaven (eibulin) injection for approval for breast cancer